EUCTR2006-004722-82-GB进行中（未招募）不适用
An exploratory study of the effects of Imatinib on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timothy grass pollen – an exploratory study of c-kit inhibition in allergic respiratory diseases
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Healthy male non-smoking subjects age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at screening.
- •2. Subjects must have a history of seasonal allergic rhinitis consistent with Timothy grass pollen allergy. They must show:
- •- a positive skin prick test to Timothy grass pollen (wheal difference Timothy grass pollen – negative control = 3 mm) at or within the 12 months preceding the screening visit and
- •- demonstrate symptomatic worsening (TNSS =4) within one hour after nasal allergen challenge
- •3. Be otherwise healthy with no health problems that may jeopardize the subjects
- •participating in the study, absence of history of other significant allergies. Subjects must weigh at least 50 kg.
- •4. Able to communicate well with the investigator, to understand and comply with the
- •requirements of the study. Understand and sign the written informed consent.
- •5. Subjects and their partners must agree to use effective contraceptive measures from screening until the end of study visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Smokers (use of tobacco products in the previous 3 months).
- •2. Presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function (FEV1 =80% predicted at screening).
- •3. Presence of any structural nasal abnormalities or nasal polyps on examination, a history of frequent nose bleeding, recent nasal surgery or recent (within 8 weeks prior to screening visit) or recent (four weeks) or ongoing upper or lower respiratory tract infection.
- •4. Use of any medication that would affect the response to the allergen challenge (e.g. corticosteroids, decongestants, anti-histamines, medications with anti-inflammatory effects) or any other nasally applied medication within 14 days prior to allergen challenge (30 days for systemic anti-inflammatory therapy including oral corticosteroids), or known to influence Imatinib bioavailability or clearance (see Section 6.3 of [Investigators Brochure, Ed. 8]).
- •5. History of allergy to imatinib.
- •6. Significant illness within two weeks prior to screening.
- •7. A past medical history of inherited heart disease, valve defect, cardiomyopathy, rheumatic fever, arrhythmias, cardia interventions or clinically significant ECG abnormalities.
- •8. History or laboratory evidence of acute or chronic renal insufficiency or abnormal liver function.
- •9. History of immunodeficiency diseases or blood borne infectious disease, including a HIV or Hepatitis B surface antigen (HBsAg) or Hepatitis C test
- •10. Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
- •11. Donation or loss of 400 ml or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- •12. Inability to use inhaled or oral medications or for any other reason deemed unable to participate in the opinion of the study investigators.
研究者
相似试验
已完成
不适用
Imatinib pharmacokinetics and its correlation with response in chronic-phase chronic myelogenous leukemiachronic myelogenous leukemia in chronic-phaseJPRN-UMIN000001125Keio University School of Medicine60
招募中
不适用
Imatinib pharmacokinetics and its correlation with response and safety in Indian children and adults with chronic phase chronic myeloid leukemia.CTRI/2010/091/000190Terry Fox Fooundation150
已完成
不适用
A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose ImatinibPER-023-09OVARTIS BIOSCIENSES PERU S.A.,
已完成
3 期
Phase III Randomized Study of Imatinib therapy in chornic phase chronic myeloid leukemia comparing standard dose-escalation with progressive dose-escalation (JALSG CML207study)Previously untreated Chronic-phase chronic myelogenous leukemiaJPRN-UMIN000000823Japan Adult Leukemia Study Group240
进行中（未招募）
1 期
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR) - CHOICES-CHlOroquine and Imatinib Combination to Eliminate Stem cellsChronic Myeloid LeukaemiaMedDRA version: 15.0Level: PTClassification code 10009013Term: Chronic myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014373-41-DEClinical Trial Center Aachen76